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The introduction of incretin hormone-based therapies represents a novel therapeutic strategy, since these drugs not only improve
glycemia with minimal risk of hypoglycemia, but also have other extraglycemic beneficial effects. These agents, which are effective
in improving glucose control, could also have positive effects on the incidence of cardiovascular events. The aim of this review
is to summarize the present literature about the role of dipeptidyl peptidase 4 (DPP4) in cardiovascular districts, not only strictly
correlated to its effect on glucagon-like peptide-1 (GLP-1) circulating levels, but also to what is known about possible cardiovascular
actions. Actually, DPP4 is known to be present in many cells and tissues and its effects go beyond purely metabolic aspects. Almost
always the inhibition ofDPP4 activity is associatedwith improved cardiovascular profile, but it has shown to possess antithrombotic
properties and these different effects could be connected with a site and/or species specificity of DPP4. Certainly, DPP4 seems to
exertmany functions, both directly and indirectly, on cardiovascular districts, opening newpossibilities of prevention and treatment
of complications at this level, not only in patients affected by diabetes mellitus.
1. Introduction
Glucagon-like peptide-1 (GLP-1) receptor agonists and dipep-
tidyl peptidase 4 (DPP4) inhibitors are currently used as
glucose-lowering agents in type 2 diabetes, due to their
effects on insulin and glucagon secretion.Many reviews show
that these agents, which are effective in improving glucose
control, could also have a beneficial effect on the incidence of
cardiovascular (CV) events. The analysis of major CV events
reported during trials with metabolic endpoints shows a sig-
nificant reduction of risk with both classes of drugs. Longer-
term trials specifically designed to assess the effects of GLP-
1 receptor agonists and DPP4 inhibitors on major cardio-
vascular events are currently ongoing. Available data suggest
that incretin-based therapies could prevent cardiovascular
disease via multiple mechanisms; in particular, pilot studies
in humans show that GLP-1 receptor agonists and DPP4
inhibitors are capable of ameliorating myocardial function
and protectmyocardiocytes from ischemic damage, indepen-
dent of their glucose-lowering effects, and both classes of
drugs enhance endothelial function [1–3]. In clinical studies,
both GLP-1 receptor agonists and DPP4 inhibitors improve
𝛽-cell function indexes; besides all these agents show trophic
effects on beta-cell mass in animal studies. Their use is
associated with positive or neutral effect on body weight and
improvements in blood pressure, diabetes-associated dyslipi-
demia, hepatic steatosis markers, and myocardial function
[4, 5]. The sum of such effects potentially reduces the burden
of cardiovascular disease, which is a major cause of mortality
in patients affected by diabetes mellitus [6].These hypotheses
advanced from evidence in animal model studies, and from
multiple meta-analyses and a retrospective study in humans.
However, no randomized controlled trials with this primary
end point have been published to date. But which is the role
of DPP4 on cardiovascular system? The aim of the present
review is to summarize the present literature about the role
of DPP4 in cardiovascular districts not only correlated to its
inhibition, but also to what is known about its possible CV
effects. A polymorphism in the DPP4 gene in patients with
knownCADmay increase the risk ofMI. Such polymorphism
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is associated with decreased plasma DPP4 level in patients
with MI [7]. DPP4 is expressed on the surface of several
cell types [8], being a transmembrane glycoprotein, with
serine exopeptidase activity that cleaves X-proline dipeptides
from the N-terminus of polypeptides. Protein dimerization
is required for catalytic activity, and glycosylation of the
enzyme impacts its physiological functions. DPP4 substrates
are proline- or alanine-containing peptides, which include
growth factors, chemokines, neuropeptides, and vasoactive
peptides [9]. Therefore, DPP4 is not specific for GLP-1
and a wide range of DPP4 substrates has been described.
Some of these may be cleaved by DPP4 only at very high
concentrations especially in supraphysiological conditions.
We know that chronic hyperglycaemia induces a significant
increase in DPP4 activity in type 1 and type 2 diabetes. This
phenomenon could contribute to the reduction in circu-
lating active glucagon-like peptide-1 and to the consequent
postprandial hyperglycaemia in type 2 diabetic patients with
poor metabolic control [10]. DPP4 is considered a novel
adipokine that may impair insulin sensitivity in an autocrine
and paracrine fashion. Furthermore, DPP4 release strongly
correlates with adipocyte size, potentially representing an
important source of DPP4 in obesity. Therefore, DPP4 could
be involved in linking adipose tissue with the metabolic
syndrome [11]. A recent review summarizes very well data
on cardiovascular effects of DPP4 inhibitors, with a spe-
cial interest in GLP-1-independent mechanisms [12]. In the
present review we have divided our analysis into three parts:
clinical studies, animal model studies, and in vitro evidence,
including only those that are correlated with the possible role
of DPP4.
2. In Vivo Evidence
2.1. Human Studies. Several prospective randomized con-
trolled clinical trials in humans with established atheroscle-
rosis have tested the effects of DPP4 inhibition on severe
cardiovascular events. In addition to their glucose-lowering
and weight-neutral or weight-reducing actions, incretin-
based therapies decrease systolic blood pressure and improve
fasting and postprandial lipid parameters, by reducing
total-cholesterol, low-density lipoprotein-cholesterol, and
triglycerides concentrations, increasing also high-density
lipoprotein-cholesterol values. Reduced high-sensitivity C-
reactive protein levels and improved endothelial dysfunction
have been also reported. Incretin-based therapies have sev-
eral beneficial effects on cardiovascular risk factors and, for
this reason, the extension of the use of these drugs in diabetic
patients with cardiovascular complications has been recently
suggested. Yet, the long-term effects of incretin-based ther-
apies on subclinical or clinical atherosclerosis remain to be
established by future studies [13]. DPP4 is known to exert
its effects via both enzymatic and nonenzymatic mecha-
nisms. A soluble form of DPP4 lacking the cytoplasmic and
transmembrane domain has also been recently recognized.
Besides enzymatic inactivation of incretins, DPP4 also medi-
ates degradation of many chemokines and neuropeptides.
The nonenzymatic function of DPP4 plays a critical role
in providing costimulatory signals to T cells via adenosine
deaminase (ADA). DPP4 may also regulate inflammatory
responses in innate immune cells such asmonocytes and den-
dritic cells. The multiplicity of functions and targets suggests
that DPP4may play a distinct role aside from its effects on the
incretin axis. Indeed recent studies in experimentalmodels of
atherosclerosis provide evidence for a robust effect for these
drugs in attenuating inflammation and plaque development
[14]. In a recent study on healthy young people DPP4 activity
is correlated with the clinical parameters of obesity and/or
diabetes. DPP4 activity displayed highly significant positive
correlation with BMI and a negative significant correlation
with the plasma adiponectin concentration (𝑃 = 0.013), but
not with fasting blood glucose [15].
2.2. Animal Models. Plasma DPP4 activity was associated
with the development of obesity, type 2 diabetes, and type
1 diabetes using animal models; in particular streptozotocin
(STZ) is commonly used to induce type 1 and late-phase
type 2 diabetic models by selective 𝛽-cell destruction in small
rodents. DPP4 deficiency delays the onset of diabetes but
worsens dyslipidaemia and renal dysfunction induced by STZ
[16].
Comparing the cardiovascular responses of ischemia/
reperfusion between wild-type and DPP4-deficient rats after
45min of coronary artery occlusion, followed by reperfusion
for 2 h, DPP4-deficient rats had better cardiac performance
in association with low infarct size and cardiac injury
markers (LDH, ANP, and BNP), which could be attenuated,
but not completely abrogated, by exendin (9–39), a GLP-1
receptor antagonist, involving a GLP-1 receptor-independent
pathway. The benefit of cardiac protective action against
ischemia/reperfusion injury was demonstrated in DPP4-
deficient rats and it was mediated through both GLP-1
receptor-dependent and receptor-independent mechanisms
[17]. The effect of chemical inhibition or genetic deletion of
DPP4 activity was studied on the cardiovascular function
in normoglycemic and diabetic mice after experimental
myocardial infarction. Cardiac structure and function were
assessed by hemodynamicmonitoring and echocardiography
in DPP4 knockout mice versus wild-type littermate controls
and after left anterior descending coronary artery ligation-
induced myocardial infarction. Increased cardiac expression
of phosphorylated AKT (pAKT), pGSK3beta, and atrial
natriuretic peptide (ANP) was detected in the nonischemic
Dpp4(−/−) heart. Sitagliptin and metformin treatment of
wild-type diabetic mice reduced mortality after myocardial
infarction. Sitagliptin improved functional recovery after
I/R injury ex vivo in WT mice with similar protection
from I/R injury also manifest in hearts from Dpp4(−/−)
versus Dpp4(+/+) mice [18]. Peripheral artery disease is
a potentially incapacitating disease whose pharmacological
options are limited. Stromal cell-derived factor-1 (SDF-1) is
a chemokine that attracts endothelial progenitor cells and
promotes angiogenesis.Therapeutic use of SDF-1 in hindlimb
ischemiamay be challenged by proteolytic degradation. SDF-
1 is a substate of DPP4. SDF-1 engineered to be resistant to
DPP4 andmatrixmetalloproteinase-2 cleavage, and delivered
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by nanofibers, improves blood flow in a model of peripheral
artery disease [19]. In vitro and in vivo, parathyroid hormone
(PTH) inhibited the activity of DPP4, which cleaves and
inactivates SDF-1. Recent data suggest that PTH inhibits
DPP4, leading to an increased concentration of plasma
SDF-1𝛼 and favoring the homing of bone-marrow-derived
CXCR4+ EPCs to sites of experimental myocardial infarction
inmice [20]. Cleavage of chemokines such as CXCL11, SDF-1,
and eotaxin by DPP4 reduces the ability of these proteins to
serve as chemoattractants to T cells and monocytes [13].
The inhibition of DPP4 protects the heart from acute
myocardial ischemia. However, the role of DPP4 in chronic
heart failure, independent of coronary artery disease, remains
unclear. Diabetic rats exhibited diastolic left ventricular
dysfunction (DHF) with enhanced interstitial fibrosis caused
partly by the increased ratio of matrix metalloproteinase-
2 to tissue inhibitor of metalloproteinase-2 in a DPP4-
dependent fashion. DPP4 inhibition reverses diastolic left
ventricular dysfunction viamembrane-bound DPP4/stromal
cell-derived factor-1𝛼-dependent local actions on angiogen-
esis and circulating DPP4/glucagon-like peptide-1-mediated
inotropic actions. Myocardium-derived DPP4 activity in
coronary sinus can be monitored by peripheral vein sam-
pling, which partly correlates with diastolic left ventricular
dysfunction index; thus, circulating DPP4 may potentially
serve as a biomarker for monitoring diastolic left ventricular
dysfunction [21]. In congestive heart failure (HF), plasma B-
type natriuretic peptide (BNP) seems devoid of biological
effectiveness. BNP(1–32) could be truncated into BNP(3–
32) by dipeptidyl peptidase 4 (DPP4), and BNP(3–32) has
reduced biological activities. Increased DPP4 activity is
associated with pathophysiology of HF. DPP4 activity was
measured in dogs with different degree of heart failure (HF):
DPP4 activity increased linearly with body weight and was
significantly higher in heart failure class 1 compared with
healthy heart and heart failure class 3 demonstrating that
DPP4 activity could be involved in early stages of heart failure
[22].
3. In Vitro Evidence
DPP4 is an enzyme produced by endothelial cells in dif-
ferent districts and circulates in plasma. DPP4 activity and
mRNA expression were measured in cultured human aortic
endothelial cells (HAEC) and human microvascular dermal
endothelial cells (HMVEC) exposed to high glucose, met-
formin, and rosiglitazone. The modulation of DPP4 activity
in endothelial cells is site specific; in fact hyperglycemia is able
to increase in a significant manner the DPP4 activity only in
microvascular endothelial cells [23]. Other authors have con-
firmed that endothelial effects of GLP-1 are mediated by an
increased nitric oxide bioavailability throughGLP-1 receptor-
dependent and -independent pathways [24]. Recently, in vitro
treatment with GLP-1 was also able to increase proliferation
of the vasculoprotective endothelial progenitor cells as shown
through an action on VEGF [25]. Besides, the relationship
between DPP4 activity and angiogenesis may be mediated by
modulation of the Neuropeptide Y (NPY) signaling that after
being processed byDPP4, NPY1–36 is converted to its shorter
form (NPY3–36), thus shifting its activity from Y1-mediated
vasoconstriction and vascular smooth muscle cell growth to
Y2/Y5-mediated angiogenesis [26]. DPP4may proteolytically
inactivate local mediators involved in gliomagenesis [27].
Almost always the inhibition of DPP4 activity is asso-
ciated with improved cardiovascular profile; in a recent
article it was shown that DPP4 also possesses antithrombotic
properties and may behave as an immobilized anticoagu-
lant on endothelial cells. Procoagulant and proinflammatory
intramyocardial (micro)vasculature plays an important role
in acute myocardial infarction (AMI). Dysfunction of the
intramyocardial microvasculature, specifically the endothe-
lium, following AMI, is suggested to relate to left ventricle
remodeling, contractility, and cardiac events, such as rein-
farction and death. Also, hindered perfusion of the ischemic
myocardium after restoration of coronary flow, known as
no-reflow or coronary microvascular obstruction (MVO),
might point to dysfunctional coronary microvasculature
and is associated with larger infarct size and poor clinical
outcome. The endothelial DPP4 expression and activity were
studied in human myocardial infarction in relation to a
prothrombogenic endothelial phenotype.
Another known DPP4 substrate is fibrin and via cleaving
N-terminal Gly-Pro from the fibrin a-chain, DPP4 can
inhibit fibrin polymerization and clot formation [28]. As
such DPP4 may behave as an immobilized anticoagulant on
(microvascular) endothelium, DPP4 expression and activity
were found on the endothelium of intramyocardial blood
vessels in autopsied control hearts. Within the infarction
area of AMI patients, this DPP4 expression and activity
were significantly decreased, corresponding to an increase in
Tissue Factor expression. In primary human umbilical vein
endothelial cells (HUVECs), DPP4 expression was strongly
decreased after metabolic inhibition, also inducing Tissue
Factor upregulation. Aggregation of platelets to endothelial
cells is a sign of thrombogenicity. Under these conditions it
was tested whether inhibition of DPP4 activity by diprotin A
in HUVECs leads to increased adherence of nonstimulated
platelets under flow conditions. The inhibition of DPP4
activity with diprotin A enhanced the amount of Tissue
Factor encountered and induced the adherence of platelets
under flow conditions. Ischemia induces loss of coronary
microvascular endothelial DPP4 expression and increased
Tissue Factor expression in AMI as well as in vitro in
HUVECs. Therefore, the reduced presence/activity of DPP4
and increased presence of Tissue Factor in the post-MI
intramyocardial microvasculature suggest a shift towards a
prothrombogenic status of the endothelium and an increased
risk of intramyocardial thrombosis.The loss of DPP4 activity
affects the antithrombogenic nature of the endothelium [29].
These effects are summarized in Figure 1.
4. Conclusions
The study of DPP4 enzymatic activity has been focused in
recent years on metabolic effects linked to degradation of
GLP-1. Actually DPP4 is known to be present in many cells
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Figure 1: Effect of DPP4 on cardiovascular districts.
and tissues and its effects go beyond purelymetabolic aspects.
Almost always the inhibition activity of DPP4 is associated
with improved cardiovascular profile, but it has shown to
possess antithrombotic properties and the different actions
could be connected with a site and/or species specificity of
DPP4. Certainly, DPP4 seems to exert many functions both
directly and indirectly on cardiovascular districts, opening
new possibilities of prevention and treatment of cardiovascu-
lar complications not only in patients with diabetes mellitus.
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